Qiagen N.V. (QGEN)
After hours:
| Previous close | 46.57 |
| Open | 46.38 |
| Bid | 45.50 x 900 |
| Ask | 45.64 x 800 |
| Day's range | 45.48 - 46.42 |
| 52-week range | 34.74 - 47.44 |
| Volume | |
| Avg. volume | 1,228,791 |
| Market cap | 10.148B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 130.46 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 30 Jan 2024 |
| 1y target est | N/A |
- GlobeNewswire
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs
Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations // Advanced capabilities support epidemiological surveillance of ongoing dengue outbreak in Brazil with unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz // Partnership highlights QIAGEN’s commitment to custom and OEM solutions, technology transfer and long-term supportVenlo, the Netherlands, Rio de Janeiro, Brazil, Sept.
- GlobeNewswire
QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease
QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications // New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with Alzheimer’s Disease // Collaboration set to launch the first commercially available IVD Kit for APOE genotypingVenlo, the Netherlands, Sept. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a collaboration with Eli Lilly and Company
- GlobeNewswire
QIAGEN N.V. announces conversion price of new net share settled convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the final terms of th
